Compare Incyte Corporation (INCY) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tyson Foods, Inc. — how do they compare? Incyte Corporation trades at $117.9 (market cap $23.11B), while Tyson Foods, Inc. trades at $57.24 (market cap $20.42B). The key difference: Incyte Corporation and Tyson Foods, Inc. are close in size by market cap, and Tyson Foods, Inc. pays a 3.52% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TSN | |
|---|---|---|
Market Cap | $23.11B | $20.42B |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $68.75 |
52-Week Low | $67.38 | $50.72 |
Enterprise Value | $19.13B | $28.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Tyson Foods (TSN) trades at $58.245, up 0.82% today, with a bearish technical signal but mixed earnings history. The company reported Q1 2026 EPS of $0.87, beating estimates, but faces margin pressures with a net income margin of 0.81%. Recent news highlights strategic product launches and executive appointments, while cash flow trends show operational strength but negative net cash flow in 2025.
Outlook is cautiously optimistic with a consensus price target of $68.80, implying 18% upside, supported by 50% analyst buy ratings. Risks include volatile protein markets and debt levels, but long-term growth in prepared foods and dividend stability offer value. Investors should weigh near-term margin challenges against strategic initiatives and analyst confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
